RELIABLE
Multiple Sclerosis affects the central nervous system. The RELIABLE project is working to slow disease progression – as early as possible and with personalised treatment.
Details
- Period: 2022-11-21 – 2025-12-01
- Budget: 3,400,000 SEK
- Funder: EU, Vinnova
Personalised medicine for Multiple Sclerosis
Multiple Sclerosis is often discovered at an early stage. There is no cure, but there are ways to slow disease progression.
The RELIABLE project is exploring the development, effect and feasibility of personalised assessment and rehabilitation for patients with Multiple Sclerosis that is discovered early on. With personalised interventions to improve patients' quality of life and to decrease the risk of future disability in patients who have not yet shown symptoms of neurological dysfunction, using a thorough assessment of comorbidities, life style, FMRIs, neuropsychological factors, gait, and balance. From this, patients receive a risk score that indicates the likelihood of disease progression in the coming year – creating prerequisites for preemptive measires like lifestyle coaching and physiotherapy.
Uppsala university's Centre for Research Ethics & Bioethics contributes special focus on patients benefit-risk tradeoffs, so called patient preferences, and how their values can contribute to the personalisation of rehabilitation and interventions. Intergrating state-of-the-art ethical framing.
Project partners
- Fondazione Don Carlo Gnocchi Onlus, Italy
- Azienda Ospedaliero Universitaria Careggi, Italy
- Sheba Medical Center, Israel
People in the project
Sylvia Martin
Research focus on newborn screening and Multiple Sclerosis. Expertise in cognitive emotional behavioral therapy, personality disorders treatment, impulsivity and consciousness.
%20SylviaMartin-photoby-JosepineFernow.PNG)
Karin Schölin Bywall
Associated researcher at CRB & Senior Lecturer at the School of Health, Care and Social Welfare, Division of Public Health Sciences, Mälardalen University.
